awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q33798909-3B1D060F-E91D-4A15-BE2F-893C5D259BE8
Q33798909-3B1D060F-E91D-4A15-BE2F-893C5D259BE8
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33798909-3B1D060F-E91D-4A15-BE2F-893C5D259BE8
Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD
P2860
Q33798909-3B1D060F-E91D-4A15-BE2F-893C5D259BE8
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33798909-3B1D060F-E91D-4A15-BE2F-893C5D259BE8
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
2eda4cf36e03f401b10f7ee885d49ad564db623e
P2860
A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.